ArticleSleep2017
CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1.
Article in Sleep, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.Journal of thoracic disease · 2026Article
- Cytokines in narcolepsy type 1: pathogenic relevance, biomarker potential, and future directions.Frontiers in neurology · 2026Review
- HLA-DQB1*03:01 strongly affects age of onset of type 1 narcolepsy independently of DQA1 and ethnicity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Association between cytokines and neuropsychiatric symptoms in paediatric narcolepsy patients: a cross-sectional study.BMC neurology · 2025Article
- Long-term follow-up of symptom and quality of life changes in patients with narcolepsy during and after the COVID-19 pandemic.Sleep and biological rhythms · 2024Article
- The immunopathogenesis of narcolepsy type 1.Nature reviews. Immunology · 2024Review
- Associations between T-cell traits and narcolepsy type 1: new insights from a Mendelian randomization study.Frontiers in neurology · 2024Article
- Narcolepsy following COVID-19: A case report and review of potential mechanisms.Clinical case reports · 2023Article
- Narcolepsy-A Neuropathological Obscure Sleep Disorder: A Narrative Review of Current Literature.Brain sciences · 2022Review
- Characterization of T cell receptors reactive to HCRTProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Orexin Signaling: A Complex, Multifaceted Process.Frontiers in cellular neuroscience · 2022Review
- Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases.Nature reviews. Neurology · 2021Review
- A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis.Scientific reports · 2021Article
- Immunotherapy in Narcolepsy.Current treatment options in neurology · 2020Review
- Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.Frontiers in immunology · 2020Article
- In vivo clonal expansion and phenotypes of hypocretin-specific CD4Nature communications · 2019Article
- Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.Nature reviews. Neurology · 2019Review
- The neurobiological basis of narcolepsy.Nature reviews. Neuroscience · 2019Review
- Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Narcolepsy type 1 is accompanied by a selective loss of orexin/hypocretin (hcrt) neurons in the lateral hypothalamus caused by yet unknown mechanisms. Epidemiologic and genetic associations strongly suggest an immune-mediated pathogenesis of the disease. Methods: We compared specific T-cell reactivity to orexin/hcrt peptides in peripheral blood mononuclear cells of narcolepsy type 1 patients to healthy controls by a carboxyfluorescein succinimidyl ester proliferation assay. Orexin/hcrt-specific T-cell reactivity was also determined by cytokine (interferon gamma and granulocyte-macrophage colony-stimulating factor) analysis. Individuals were considered as responders if the cell division index of CD3+CD4+ T cells and both stimulation indices of cytokine secretion exceeded the cutoff 3. Additionally, T-cell reactivity to orexin/hcrt had to be confirmed by showing reactivity to single peptides present in different peptide pools. Results: Using these criteria, 3/15 patients (20%) and 0/13 controls (0%) showed orexin/hcrt-specific CD4+ T-cell proliferation (p = .2262). The heterogeneous reactivity pattern did not allow the identification of a preferential target epitope. Conclusions: A significant role of orexin/hcrt-specific T cells in narcolepsy type 1 patients could not be confirmed in this study. Further studies are needed to assess the exact role of CD4+ T cells and possible target antigens in narcolepsy type 1 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.